Cerus Corporation (NASDAQ:CERS) Receives Media Impact Score of 0.13

Media headlines about Cerus Corporation (NASDAQ:CERS) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerus Corporation earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.0653315421025 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Cerus Corporation (NASDAQ:CERS) traded up 1.77% on Friday, hitting $2.88. 544,882 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $2.81 and its 200-day moving average price is $2.79. Cerus Corporation has a 12-month low of $1.93 and a 12-month high of $5.91. The company’s market cap is $314.31 million.

Cerus Corporation (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The company had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. Cerus Corporation’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.18) EPS. Analysts forecast that Cerus Corporation will post ($0.64) earnings per share for the current year.

A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Zacks Investment Research cut shares of Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Cowen and Company set a $6.00 target price on shares of Cerus Corporation and gave the company a “buy” rating in a research report on Thursday, October 5th. Finally, ValuEngine cut shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $7.00.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/27/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cerus-corporation-cers-share-price.html.

In other news, insider Laurence M. Corash acquired 92,796 shares of the business’s stock in a transaction on Friday, August 11th. The stock was bought at an average price of $2.45 per share, for a total transaction of $227,350.20. Following the transaction, the insider now owns 1,375,711 shares in the company, valued at $3,370,491.95. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.40% of the stock is currently owned by corporate insiders.

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply